Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Valneva ( (VALN) ) has shared an update.
On February 19, 2026, Valneva reported preliminary unaudited 2025 results showing total revenue of €174.7 million, broadly flat year on year, with product sales of €157.9 million and a sharp, expected 42.3% decline in third‑party sales. Cash and cash equivalents stood at €109.7 million at year‑end after debt refinancing, and product sales excluding third‑party items grew 9% at constant exchange rates, underscoring resilience in its core travel vaccine portfolio.
For 2026, the company guided total revenue of €155‑170 million and product sales of €145‑160 million, reflecting growth in proprietary brands but a continued wind‑down of third‑party volumes. Management flagged 2026 as potentially transformational with a Phase 3 data readout for its Lyme disease vaccine VLA15 in the first half and Phase 2 data for its Shigella candidate, while renewing CEO Thomas Lingelbach’s mandate for three more years to secure strategic continuity and support ongoing R&D‑led expansion.
The most recent analyst rating on (VALN) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The group leverages multiple vaccine modalities and currently markets three proprietary travel vaccines, while reinvesting commercial revenues into a pipeline that includes advanced Lyme disease and Shigella vaccine candidates, alongside other public‑health focused programs.
Average Trading Volume: 19,072
Technical Sentiment Signal: Buy
Current Market Cap: $940.5M
See more insights into VALN stock on TipRanks’ Stock Analysis page.